023910 — Dai Han Pharm Co Income Statement

0.000.00%

Last trade - 00:00

HealthcareConservativeSmall CapSuper Stock

Annual income statement for Dai Han Pharm Co, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.

	2020 December 31st	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	Annual Audited Accounts	Annual Audited Accounts	ARS	ARS	ARS
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	166,080	171,463	184,268	195,911	204,195
Cost of Revenue
Gross Profit	56,536	56,039	60,242	65,922	69,788
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Total Operating Expenses	136,147	142,528	151,399	160,197	166,161
Operating Profit	29,933	28,935	32,868	35,714	38,034
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	22,532	30,433	33,451	36,734	42,329
Provision for Income Taxes
Net Income After Taxes	17,381	22,670	24,961	28,426	33,759
Net Income Before Extraordinary Items
Net Income	17,381	22,670	24,961	28,426	33,759
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	17,381	22,670	24,961	28,426	33,759
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	3,882	3,790	4,184	4,842	5,740
Dividends per Share